South Korea · Delayed Price · Currency is KRW BCWORLD PHARM. Statistics
Total Valuation
BCWORLD PHARM. has a market cap or net worth of KRW 32.33 billion. The enterprise value is 116.88 billion.
| Market Cap | 32.33B |
| Enterprise Value | 116.88B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
BCWORLD PHARM. has 10.17 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 10.17M |
| Shares Outstanding | 10.17M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | +57.09% |
| Owned by Insiders (%) | 42.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 14.90 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.46 |
| EV / EBITDA | 9.30 |
| EV / EBIT | 25.99 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.56, with a Debt / Equity ratio of 1.21.
| Current Ratio | 0.56 |
| Quick Ratio | 0.27 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | 6.95 |
| Debt / FCF | -32.51 |
| Interest Coverage | 1.09 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on invested capital (ROIC) is -2.57%.
| Return on Equity (ROE) | -0.66% |
| Return on Assets (ROA) | 1.62% |
| Return on Invested Capital (ROIC) | -2.57% |
| Return on Capital Employed (ROCE) | 5.09% |
| Weighted Average Cost of Capital (WACC) | -0.94% |
| Revenue Per Employee | 285.04M |
| Profits Per Employee | -8.96M |
| Employee Count | 280 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.30 |
Taxes
In the past 12 months, BCWORLD PHARM. has paid 1.03 billion in taxes.
| Income Tax | 1.03B |
| Effective Tax Rate | 188.06% |
Stock Price Statistics
The stock price has decreased by -22.13% in the last 52 weeks. The beta is 0.63, so BCWORLD PHARM.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -22.13% |
| 50-Day Moving Average | 3,909.80 |
| 200-Day Moving Average | 4,458.63 |
| Relative Strength Index (RSI) | 34.00 |
| Average Volume (20 Days) | 14,903 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BCWORLD PHARM. had revenue of KRW 79.81 billion and -2.51 billion in losses. Loss per share was -270.07.
| Revenue | 79.81B |
| Gross Profit | 31.89B |
| Operating Income | 4.50B |
| Pretax Income | 546.64M |
| Net Income | -2.51B |
| EBITDA | 12.57B |
| EBIT | 4.50B |
| Loss Per Share | -270.07 |
Balance Sheet
The company has 4.45 billion in cash and 87.33 billion in debt, with a net cash position of -82.88 billion or -8,152.42 per share.
| Cash & Cash Equivalents | 4.45B |
| Total Debt | 87.33B |
| Net Cash | -82.88B |
| Net Cash Per Share | -8,152.42 |
| Equity (Book Value) | 72.36B |
| Book Value Per Share | 6,915.74 |
| Working Capital | -37.76B |
Cash Flow
In the last 12 months, operating cash flow was 2.17 billion and capital expenditures -4.86 billion, giving a free cash flow of -2.69 billion.
| Operating Cash Flow | 2.17B |
| Capital Expenditures | -4.86B |
| Depreciation & Amortization | 8.07B |
| Net Borrowing | -362.85M |
| Free Cash Flow | -2.69B |
| FCF Per Share | -264.26 |
Margins
Gross margin is 39.95%, with operating and profit margins of 5.64% and -3.14%.
| Gross Margin | 39.95% |
| Operating Margin | 5.64% |
| Pretax Margin | 0.68% |
| Profit Margin | -3.14% |
| EBITDA Margin | 15.74% |
| EBIT Margin | 5.64% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 90.91, which amounts to a dividend yield of 2.78%.
| Dividend Per Share | 90.91 |
| Dividend Yield | 2.78% |
| Dividend Growth (YoY) | 10.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | 2.60% |
| Earnings Yield | -7.76% |
| FCF Yield | -8.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 29, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Dec 29, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
BCWORLD PHARM. has an Altman Z-Score of 0.82 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.82 |
| Piotroski F-Score | 6 |